• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

Enabling Statisticians to Lead through Innovation and Excellence

    Enabling Statisticians to Lead through Innovation and Excellence

Search The Effective Statistician

  • Winning with Words and Graphs: The Effective Statistician presentation and data visualization masterclass
  • How to be an effective statistician
  • Start here!
  • Podcast
    • PSI Careers
  • Free resources on visualization
    • Recording available: Flatten the curve – learnings from COVID-19 visualizations to better explore and communicate your data
  • Free resources on influencing
    • The Effective Statistician Leadership Program
    • Recording available: It’s not enough to be right!
  • Join The Effective Statistician LinkedIn group
  • Quick tips to be more effective
  • Legal disclosure – about us
    • Datenschutzerklärung – sorry, still in German…
You are here: Home / Innovation / The benefit-risk tolerability measure – a new way to reach insights into benefit-risk and more

The benefit-risk tolerability measure – a new way to reach insights into benefit-risk and more

By Reine Escalona on 2020-11-11 0

The benefit-risk tolerability measure – a new way to reach insights into benefit-risk and more
  • share 
  • tweet  
  • share  
  • share 
  • save  

Interview with Yves Schymura

Yves and I have worked together in various roles. Over time, he became more interested in becoming a statistician and I helped him to change his career path in this direction.

As part of his master thesis, he worked on an idea; I had sketched out a couple of years ago but never had the time to fully think through. I wanted to explore how we could utilize existing study data to inform the benefit-risk assessment of different therapies. In this episode, you will learn a new concept which also is related to minimal clinical meaningful differences and helps to assess the impact of various adverse events on the patient. Specifically, we dive into:

  • What is the benefit-risk tolerability measure?
  • How can we use the information on which patient discontinue to inform the benefit-risk assessment?
  • How does the model help us rank adverse events in order of their importance?
  • Which adverse events cannot be classified with the model?
  • How to use the model to inform relevant difference for efficacy endpoints?

Dr. Yves Schymura

Associate Consultant Statistician at Lilly Deutschland GmbH

He studied Physiological Sciences and Pharmacology at the University of Oxford before pursuing his doctoral studies at the Max-Planck-Institute for Heart and Lung Research. For the past 7 years he worked in the German HTA context with increasing roles of responsibility, at last as HTA Team Lead / Early Pipeline Team Lead Immunology at AbbVie. During that time he discovered his passion for data and how to best use it to enable insight, effectively communicate results and generate value. 

In 2019 the finished his extra-occupational study of Medical Biometry / Biostatistics at the University of Heidelberg, his master’s thesis dealing with a novel method on how to judge the patient relevance of adverse events using data from clinical trials to inform benefit-risk assessments. Since then he is working as a statistician in the international business unit of Lilly in the areas of medical affairs and HTA. In his spare time he enjoys spending time with his family, in the outdoors and is an avid cyclist.

Listen to this episode and share it with your friends and colleagues!

Never miss an episode of The Effective Statistician

Join hundreds of your peers and subscribe to get our latest updates by email!

Get the shownotes of our podcast episodes plus tips and tricks to increase your impact at work to boost your career!

Success! Now check your email to confirm your subscription.

There was an error submitting your subscription. Please try again.

We won't send you spam. Unsubscribe at any time. Powered by ConvertKit
  • share 
  • tweet  
  • share  
  • share 
  • save  

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Primary Sidebar

Join the PSI newsletter here!

Categories

  • Excellence
  • Innovation
  • Knowledge
  • Leadership
  • PSI Calc Podcast

Recent Posts

  • Extrapolation to paedriatics
  • How to integrate external data into your clinical studies: from theory to application
  • A preview into the PSI conference
  • Patient-reported outcomes and the FDA Patient-Focused Drug Development Guidance
  • Apps on prescription paid by the government

Archives

  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018

The podcast is run in association with PSI

Copyright © 2022 · Smart Passive Income Pro on Genesis Framework · WordPress · Log in